These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3378598)

  • 1. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes.
    Hellström E; Robèrt KH; Gahrton G; Mellstedt H; Lindemalm C; Einhorn S; Björkholm M; Grimfors G; Udén AM; Samuelsson J
    Eur J Haematol; 1988 May; 40(5):449-59. PubMed ID: 3378598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
    Hellström E; Robèrt KH; Samuelsson J; Lindemalm C; Grimfors G; Kimby E; Oberg G; Winqvist I; Billström R; Carneskog J
    Eur J Haematol; 1990 Nov; 45(5):255-61. PubMed ID: 2261951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
    Aul C; Schneider W
    Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of low dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes--analysis of factors influencing the duration of responses, survival and clinical effects].
    Sawada H; Abe T; Akasaka K; Ishikura H; Izumi Y; Inamoto Y; Usui T; Okazaki T; Okada H; Katoh Y
    Rinsho Ketsueki; 1987 Sep; 28(9):1553-60. PubMed ID: 3437517
    [No Abstract]   [Full Text] [Related]  

  • 6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
    Burnett AK; Milligan D; Prentice AG; Goldstone AH; McMullin MF; Hills RK; Wheatley K
    Cancer; 2007 Mar; 109(6):1114-24. PubMed ID: 17315155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N; Tanaka I; Minami N; Shirakawa S
    Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
    Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
    Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
    Nair R; Nair CN; Advani SH
    Leuk Lymphoma; 1998 Mar; 29(1-2):187-92. PubMed ID: 9638988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes.
    Hellström E; Robèrt KH; Soppi E; Ost A; Putkonen PO; Gahrton G
    Leuk Res; 1989; 13(12):1113-21. PubMed ID: 2615468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
    Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
    Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C.
    Letendre L; Noel P; White WL; Tefferi A; Litzow MR; Li CY; Schroeder G
    Leuk Res; 1999 Sep; 23(9):811-5. PubMed ID: 10475620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
    Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N
    Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Kornblau SM; Cortes-Franco J; Estey E
    Leukemia; 1993 Mar; 7(3):378-83. PubMed ID: 8445943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
    Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
    Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.